| Bid | 2.71 |
| Market Cap | 24.70M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.25 |
| PE Ratio (ttm) | -10.8 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 2.74 |
| Volume | 19,092 |
| Avg. Volume (20D) | 109,957 |
| Open | 2.77 |
| Previous Close | 2.73 |
| Day's Range | 2.66 - 2.77 |
| 52-Week Range | 1.02 - 4.98 |
| Beta | undefined |
About IBIO
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing ...
Analyst Forecast
According to 3 analyst ratings, the average rating for IBIO stock is "Buy." The 12-month stock price forecast is $5, which is an increase of 85.19% from the latest price.
9 months ago · proactiveinvestors.com
iBio partners with AstralBio to develop obesity treatments using AI-driven platformiBio, an AI-driven drug developer, shares surged more than 120% after it announced it has entered into a collaboration agreement with private biotech firm AstralBio to discover, engineer and develop n...
